S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Buy THIS stock before Taiwan is attacked (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
Biden To Unleash "Choke Point" Operation On America? (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Buy THIS stock before Taiwan is attacked (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
Biden To Unleash "Choke Point" Operation On America? (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Buy THIS stock before Taiwan is attacked (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
Biden To Unleash "Choke Point" Operation On America? (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Buy THIS stock before Taiwan is attacked (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
Biden To Unleash "Choke Point" Operation On America? (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
NYSE:TAK

Takeda Pharmaceutical - TAK Stock Forecast, Price & News

$16.36
+0.14 (+0.86%)
(As of 03/24/2023 08:51 PM ET)
Add
Compare
Today's Range
$16.19
$16.37
50-Day Range
$15.28
$16.44
52-Week Range
$12.28
$16.58
Volume
1.42 million shs
Average Volume
2.78 million shs
Market Capitalization
$51.77 billion
P/E Ratio
24.79
Dividend Yield
3.30%
Price Target
$22.00

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
34.5% Upside
$22.00 Price Target
Short Interest
Healthy
0.16% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.18mentions of Takeda Pharmaceutical in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

327th out of 1,005 stocks

Pharmaceutical Preparations Industry

146th out of 486 stocks


TAK stock logo

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

Price Growth & Yield: For That Magical Combo, Leave the U.S. (TAK)
Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Dry Eye Disease (DED) Market by 2031
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Penicillin Market Size and Forecast till 2028
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Last Earnings
2/02/2023
Today
3/26/2023
Fiscal Year End
3/31/2023
Next Earnings (Estimated)
5/10/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
47,347
Year Founded
1781

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+34.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$2.05 billion
Pretax Margin
6.23%

Debt

Sales & Book Value

Annual Sales
$31.79 billion
Cash Flow
$3.61 per share
Book Value
$16.31 per share

Miscellaneous

Outstanding Shares
3,164,590,000
Free Float
3,163,325,000
Market Cap
$51.77 billion
Optionable
Optionable
Beta
0.64

Social Links


Key Executives

  • Christophe Weber
    President, CEO & Representative Director
  • Constantine Saroukos
    Chief Financial Officer & Director
  • Andrew S. Plump
    Director, President-Research & Development
  • Michael E. Mendelsohn
    Chief Medical & Scientific Officer
  • Norimasa Takeda
    Chief Accounting Officer & Corporate Controller













TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings
or view top-rated stocks.

What is Takeda Pharmaceutical's stock price forecast for 2023?

4 Wall Street research analysts have issued 12-month price targets for Takeda Pharmaceutical's shares. Their TAK share price forecasts range from $20.00 to $24.00. On average, they anticipate the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 34.5% from the stock's current price.
View analysts price targets for TAK
or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2023?

Takeda Pharmaceutical's stock was trading at $15.60 at the start of the year. Since then, TAK stock has increased by 4.9% and is now trading at $16.36.
View the best growth stocks for 2023 here
.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our TAK earnings forecast
.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) issued its quarterly earnings results on Thursday, February, 2nd. The company reported $0.46 earnings per share for the quarter. The business earned $8.40 billion during the quarter. Takeda Pharmaceutical had a trailing twelve-month return on equity of 12.43% and a net margin of 6.84%.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.54 per share and currently has a dividend yield of 3.33%. The dividend payout ratio is 81.82%. Payout ratios above 75% are not desirable because they may not be sustainable.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2022 earnings guidance on Thursday, February, 2nd. The company provided earnings per share guidance of $3.72-$3.72 for the period. The company issued revenue guidance of $27.84 billion-$27.84 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (0.15%), Mondrian Investment Partners LTD (0.14%), Clal Insurance Enterprises Holdings Ltd (0.14%), Arrowstreet Capital Limited Partnership (0.13%), Macquarie Group Ltd. (0.12%) and Renaissance Technologies LLC (0.09%).

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $16.36.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $51.77 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.66 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

The company employs 47,347 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 3/27/2023 by MarketBeat.com Staff